Pharmacytimes offers continuing education (CE) courses, career guidance for pharmacy students, online-only articles, digital versions of the print issue, and more, that are essential to pharmacists en-us Wed, 12 Dec 18 08:00:30 +0000 Wed, 12 Dec 18 08:00:30 +0000 FDA Clears Prescription-Only App for Treating Opioid Use Disorder The application is designed to help increase patient retention for adults in outpatient treatment programs. Mon, 10 Dec 18 22:55:00 +0000 Mylan Expands Voluntary Nationwide Recall of Valsartan Tablets These products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in the API valsartan. Tue, 04 Dec 18 17:09:00 +0000 Monday Pharmaceutical Mystery: December 3 Can you solve the pharmaceutical mystery? Each week, a new case study is presented.&nbsp; Mon, 03 Dec 18 15:00:00 +0000 What's on the Horizon for Immunotherapy? Immunotherapy was first linked to cancer treatment in the late 19th century when surgeon William Coley discovered that the injection of bacteria into sarcoma sites led to tumor shrinkage. Thu, 29 Nov 18 18:00:00 +0000 First Treatment for Rare Autoimmune Disorder Receives FDA Approval Amifampridine (Firdapse) is a first-in-class therapy for Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder.<br /> &nbsp; Thu, 29 Nov 18 14:21:00 +0000 Gilteritinib Granted FDA Approval for Adults with Acute Myeloid Leukemia The drug&rsquo;s application was designated for fast track and priority review, as well as orphan product status.<br /> &nbsp; Wed, 28 Nov 18 19:50:00 +0000 FDA Approves First Biosimilar for Non-Hodgkin's Lymphoma Rituximab-abbs (Truxima, Celltrion) is the fifteenth biosimilar approved by the FDA and the sixth biosimilar approved in 2018, thus far.<br /> &nbsp; Wed, 28 Nov 18 19:35:00 +0000 CVS Finalizes Acquisition of Aetna and Looks to the Future CVS Health announced that it has closed its acquisition of Aetna with the promise to transform the consumer health experience.<br /> &nbsp; Wed, 28 Nov 18 17:46:00 +0000 New Recall Announced for Products Containing Valsartan Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine/Valsartan combination tablets and Amlodipine Valsartan/Hydrochlorothiazide combination tablets, due to an impurity detected above specification limits in an active pharmaceutical ingredient (API) manufactured by Mylan India. Wed, 28 Nov 18 02:06:00 +0000 FDA Grants Onc Drug Accelerated Approval for Key Genetic Driver of Cancer The FDA has granted an accelerated approval to larotrectinib (Vitrakvi, Loxo Oncology) for the treatment of adult and pediatric patients with solid tumors that have an&nbsp;NTRKgene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment. Mon, 26 Nov 18 22:58:00 +0000 New Autoinjector Formulation for Tocilizumab Granted FDA Approval The single-dose, prefilled autoinjector for tocilizumab (Actemra) offers an additional option for patients with rheumatoid arthritis, giant cell arteritis, and 2 forms of juvenile arthritis. Mon, 26 Nov 18 17:42:00 +0000 First-ever Multidrug Ebola Trial Launches More than 160 patients have thus far been treated with investigational therapeutics under an ethical framework developed by WHO. Mon, 26 Nov 18 13:35:00 +0000 Take the Pharmacy Times Salary and Job Satisfaction Survey Our editors want to know all about pharmacists&#39; compensation and how happy they are with their jobs.<br /> &nbsp; Fri, 23 Nov 18 15:00:00 +0000 FDA Grants Accelerated Approval to Venetoclax With this approval, venetoclax (Venclexta) offers a new treatment option for individuals who are unable to tolerate standard intensive chemotherapy.<br /> &nbsp; Wed, 21 Nov 18 20:00:00 +0000 Glasdegib: New Treatment Approved by FDA for Patients with AML Glasdegib (Daurismo) is the first and only Hedgehog pathway inhibitor approved for the treatment of acute myeloid leukemia.<br /> &nbsp; Wed, 21 Nov 18 19:54:00 +0000 FDA: Stopping Treatment with MS Drug Gilenya Carries Risk of Severe Disease Worsening FDA officials are warning that stopping treatment with the multiple sclerosis (MS) drug fingolimod (Gilenya) can cause severe worsening. Wed, 21 Nov 18 01:38:00 +0000 FDA OKs First Treatment for Pediatric, Adult Patients with Rare Immune Disease Officials with the FDA have approved emapalumab (Gamifant) for the treatment of pediatric and adult patients with primary hemophagocytic lymphohistiocytosis (HLH), making it the first FDA-approved drug specifically indicated for this disease. Tue, 20 Nov 18 15:38:00 +0000 Eltrombopag Granted FDA Approval for Severe Aplastic Anemia he FDA has expanded the approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy (IST) to include newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia. Sun, 18 Nov 18 12:00:00 +0000 First-line Treatment for PTCL Granted FDA Approval Under New Review Pilot The FDA has expanded the approved use of Seattle Genetics&rsquo; Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma (PTCL). Fri, 16 Nov 18 19:00:00 +0000 E-Cigarette Use Rising Among Youth A significant increase in e-cigarette use among middle school and high school students in the United States has driven an overall rise in youth tobacco consumption, according to survey results released by the FDA and the CDC. Fri, 16 Nov 18 15:23:00 +0000 Survey: Pharmacists Want to Expand Role in Patient Care, but Burdens Must Lessen The findings revealed that 78% of pharmacists across pharmacy settings look forward to playing a greater role in patient care and the majority expect to spend more time on patient-focused activities in the next 5 years. Thu, 15 Nov 18 16:33:00 +0000 FDA Grants Priority Review to Combination Treatment for Initial TNBC The FDA has accepted Genentech&rsquo;s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq<sup>&reg;</sup>&nbsp;(atezolizumab) plus chemotherapy (Abraxane<sup>&reg;</sup>&nbsp;[albumin-bound paclitaxel;&nbsp;<em>nab</em>-paclitaxel]) for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) in people whose disease expresses the PD-L1 protein, as determined by PD-L1 biomarker testing. Wed, 14 Nov 18 14:00:00 +0000 One Health Brings Together Different Health Sectors to Fight Antibiotic Resistance In this clip, Debra Goff, PharmD, FCCP, infectious disease clinical pharmacist and Associate Professor at The Ohio State University, tells <em>Pharmacy Times</em> about One Health, a movement dedicated to bringing together different fields that handle antibiotics to prevent the misuse of these bacteria-killing drugs.&nbsp; Tue, 13 Nov 18 22:17:00 +0000 Top 5 Podcasts for Pharmacists Stay up to date on the latest clinical information, and get tips for personal and professional development. Tue, 13 Nov 18 21:56:00 +0000 Updated Guidelines Advise on Outpatient Parenteral Antimicrobial Therapy New research underscores the value of review by an ID physician, nurse, or pharmacist before starting OPAT. Tue, 13 Nov 18 16:44:00 +0000